switching from compounded semaglutide to tirzepatide Tirzepatide: A Provider's Guide What to Expect When Switching

Citing the drugs negative effects on muscle mass and bone density, Akradi believes it will be an epidemic if its not handled correctly. Meeting the moment, gym operators have the opportunity to position themselves as the missing layer between weight-loss drugs and long-term health where movement and medicine go hand in hand

3 min readThe First Quarter 2026 newsletter of AHA Coding Clinic for ICD-10-CM and ICD-10-PCS is now available

A 2024 RCT found semaglutide reduced hip bone density by 2.6% and lumbar spine by 2.1% in one year

Novo Nordisk just played one of its most strategic cards in the obesity drug race

The more meaningful question is not: Do patients regain weight after stopping GLP-1s? It is: How should we transition patients from pharmacologic support to long-term weight maintenance? Obesity is a chronic disease

Tirzepatide for womens weight loss: discover how GLP-1/GIP therapy helps overcome hormonal resistance, reduce cravings, and deliver up to 20% sustainable fat loss.